Elicio Therapeutics, Inc.
ELTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $62 | $42 | $18 | $19 |
| - Cash | $18 | $13 | $6 | $9 |
| + Debt | $26 | $7 | $7 | $12 |
| Enterprise Value | $71 | $36 | $20 | $21 |
| Revenue | $0 | $0 | $0 | $28 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$1 | -$1 | -$1 | $27 |
| % Margin | – | – | – | 95.6% |
| EBITDA | -$50 | -$33 | -$24 | -$52 |
| % Margin | – | – | – | -183.4% |
| Net Income | -$52 | -$35 | -$28 | -$26 |
| % Margin | – | – | – | -93.2% |
| EPS Diluted | -4.25 | -6.96 | -9.1 | -19.32 |
| % Growth | 38.9% | 23.5% | 52.9% | – |
| Operating Cash Flow | -$37 | -$33 | -$22 | -$24 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$37 | -$33 | -$23 | -$24 |